| 1 |
32695000 | ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. | 2020 |
3 |
| 2 |
30925062 | Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach. | 2019 May 9 |
2 |
| 3 |
31141714 | Comments on: "Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan". | 2019 Jul |
1 |
| 4 |
31141715 | Comments on: "Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan". | 2019 Jul |
1 |
| 5 |
27845419 | ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. | 2018 Jan |
3 |
| 6 |
29499902 | Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity. | 2018 Dec 14 |
1 |
| 7 |
29861877 | SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. | 2018 May 18 |
1 |
| 8 |
29873288 | Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations. | 2018 Jun |
3 |
| 9 |
30135242 | Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestine. | 2018 Nov |
2 |
| 10 |
30213564 | Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. | 2018 Oct |
2 |
| 11 |
29016119 | 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein. | 2017 Nov 9 |
1 |
| 12 |
27269636 | Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis. | 2016 Jun |
1 |
| 13 |
26206183 | Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. | 2015 Sep 1 |
2 |
| 14 |
26352872 | ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. | 2015 Dec |
1 |
| 15 |
26692923 | FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. | 2015 |
2 |
| 16 |
24588516 | Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice. | 2014 Dec |
2 |
| 17 |
25195021 | Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method. | 2014 Oct 15 |
1 |
| 18 |
25454761 | Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation. | 2014 Nov 1 |
1 |
| 19 |
23801203 | [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer]. | 2013 Jun |
3 |
| 20 |
23850745 | Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation. | 2013 Nov 1 |
1 |
| 21 |
23953030 | A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). | 2013 Nov |
4 |
| 22 |
24457609 | Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk. | 2013 |
2 |
| 23 |
23149859 | Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. | 2012 Dec 14 |
4 |
| 24 |
20177420 | Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. | 2011 Feb |
2 |
| 25 |
21459094 | Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. | 2011 Jul |
3 |
| 26 |
21787264 | Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. | 2011 Dec |
1 |
| 27 |
19771428 | Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. | 2010 May |
1 |
| 28 |
19862647 | MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. | 2010 Dec |
11 |
| 29 |
20205661 | Pharmacogenetics in oncology: a promising field. | 2010 |
1 |
| 30 |
20829196 | I-387, a novel antimitotic indole, displays a potent in vitro and in vivo antitumor activity with less neurotoxicity. | 2010 Nov |
2 |
| 31 |
19262372 | Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. | 2009 Apr |
2 |
| 32 |
19349540 | Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. | 2009 Jun 1 |
2 |
| 33 |
18558463 | Clinical and pharmacogenetic factors associated with irinotecan toxicity. | 2008 Nov |
1 |
| 34 |
18579105 | Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. | 2008 Aug 11 |
2 |
| 35 |
18703021 | Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). | 2008 Oct 1 |
1 |
| 36 |
17534875 | Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. | 2007 Jul 1 |
2 |
| 37 |
17666793 | Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. | 2007 Aug |
3 |
| 38 |
19356014 | ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. | 2007 Jan |
1 |
| 39 |
16271446 | Pharmacogenetics of irinotecan metabolism and transport: an update. | 2006 Mar |
1 |
| 40 |
16343744 | Role of pharmacogenetics in irinotecan therapy. | 2006 Mar 8 |
1 |
| 41 |
16508919 | Expression of drug pathway proteins is independent of tumour type. | 2006 Jun |
1 |
| 42 |
15801936 | Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. | 2005 Apr |
4 |
| 43 |
16098482 | MRP1 mutated in the L0 region transports SN-38 but not leukotriene C4 or estradiol-17 (beta-D-glucuronate). | 2005 Oct 1 |
1 |
| 44 |
16132345 | Human multidrug resistance associated protein 4 confers resistance to camptothecins. | 2005 Nov |
4 |
| 45 |
12914384 | Pharmacogenetics of stomach cancer. | 2003 Sep-Oct |
1 |
| 46 |
12960109 | Irinotecan pathway genotype analysis to predict pharmacokinetics. | 2003 Aug 15 |
3 |
| 47 |
14646693 | Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. | 2003 Dec |
2 |
| 48 |
11395570 | Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. | 2001 Jun |
3 |
| 49 |
10912951 | Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. | 2000 Jun |
2 |
| 50 |
9918583 | Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. | 1999 Feb |
2 |